Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Ginkgo Bioworks Holdings Inc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M), while Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 33× Avalanche Treasury Corporation Class A Common Stock's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AVAT | DNA | |
|---|---|---|
Market Cap | $15.33M | $505.73M |
Sector | Financials | Health |
52-Week High | $10.75 | $16.14 |
52-Week Low | $0.30 | $5.48 |
Enterprise Value | $15.33M | $607.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT trades at $0.342, up 1.57% on the day, with a bearish technical signal from moving averages. The company reported a net income of $8.28 million for the current period but negative operating cash flow of -$930,710, indicating potential cash burn. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed; a low P/B of 0.4 suggests potential undervaluation, but negative cash flow and a bearish technical trend pose risks. Investment opportunity hinges on the company's ability to improve operational efficiency post-listing, while risks include sustained cash burn and competitive pressures in treasury management.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
